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Abstract 
Background: Tafenoquine is a long half-life primaquine analog being developed for malaria prophylaxis. The US 
Army recently performed a unified analysis of efficacy in preparation for a regulatory submission, utilizing legacy data 
from three placebo-controlled studies conducted in the late 1990s and early 2000s. The subjects were residents of 
Africa who were naturally exposed to Plasmodium falciparum for 12–26 weeks.
Methods: The prophylactic efficacy of tafenoquine and mefloquine (included in some studies as a comparator) was 
calculated using incidence density among subjects who had completed the three-day loading doses of study drug, 
had at least one maintenance dose and had at least one blood smear assessed during the prophylactic period. The 
three placebo-controlled studies were analysed separately and then in two pooled analyses: one for tafenoquine 
versus placebo (three studies) and one for tafenoquine and mefloquine versus placebo (two studies).
Results: The pooled protective efficacy (PE) of a tafenoquine regimen with three daily loading doses plus weekly 
maintenance at 200-mg for 10 weeks or longer (referred to as 200-mg weekly hereafter) relative to placebo in three 
placebo-controlled studies was 93.1 % [95 % confidence interval (CI) 89.1–95.6 %; total N = 492]. The pooled PEs of 
regimens of tafenoquine 200-mg weekly and mefloquine 250-mg weekly relative to placebo in two placebo-con-
trolled studies (total N = 519) were 93.5 % (95 % CI 88.6–96.2 %) and 94.5 % (95 % CI 88.7–97.3 %), respectively. Three 
daily loading plus weekly maintenance doses of 50- and 100-mg, but not 25-mg, exhibited similar PEs. The PEs of 
tafenoquine regimens of a three-day loading dose at 400-mg with and without follow-up weekly maintenance doses 
at 400-mg were 93.7 % (95 % CI 85.4–97.3 %) and 81.0 % (95 % CI 66.8–89.1 %), respectively.
Conclusions: Tafenoquine provided the same level of prophylactic efficacy as mefloquine in residents of Africa. 
These data support the prophylactic efficacy of tafenoquine and mefloquine that has already been demonstrated in 
the intended malaria naive population.
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Background
Tafenoquine, due to its long half-life, blood schizonticidal 
activity, inhibitory effect on developing exoerythrocytic 
schizonts and anti-relapse efficacy against Plasmodium 
vivax hypnozoites, may fill a valuable niche that is unoc-
cupied by marketed anti-malarial agents. In the 1990s 
and early 2000s, a series of three placebo-controlled 
studies (Studies 030, 043, and 045) were conducted to 
assess the safety and prophylactic efficacy of weekly and 
monthly regimens of tafenoquine at various doses as well 
as the comparator prophylactic drug, mefloquine, among 
the residents of malaria-endemic countries (Kenya and 
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Ghana) [1–4]. The results of two of those three stud-
ies (Studies 043, and 045) were reported elsewhere. The 
objective of the present work was to present the pro-
tective efficacy (PE) of tafenoquine in all three of these 
studies and pooled analysis results in a uniform manner, 
including a retrospective re-analysis of one of the stud-
ies that has not been previously described (Study 030). 
This analysis is consistent with the observations of a 
prior prophylaxis study in malaria-naive Australian sol-
diers deployed to Timor-Leste for peace keeping opera-
tions who received either mefloquine or tafenoquine 
chemoprophylaxis [5]. No malaria cases were observed 
in subjects taking either drug, and the point estimates of 
efficacy were estimated retrospectively to be 100 % (95 % 




All three studies, either presented as individual studies 
or used in the pooled analysis, were placebo-controlled, 
randomized, double-blind clinical evaluations of the effi-
cacy of tafenoquine compared with that of mefloquine 
or placebo in the prophylaxis of malaria. All three study 
protocols were very similar and the studies were con-
ducted in a similar manner. Study participants were adult 
Africans who were living in an area endemic for Plas-
modium falciparum malaria. All three studies employed 
a design that started with a clearance period to clear 
existing parasitaemia; then, usually a few days later, the 
loading period began, with daily study drug adminis-
tration for three consecutive days. This period was fol-
lowed immediately by a maintenance period with weekly 
study drug administration. In all studies, blood samples 
were collected weekly from study participants during 
the entire study for parasitological assessment. Informed 
consent was obtained from all study subjects, and all 
studies were approved by competent institutional review 
boards. Below, a brief summary is provided for each of 
the studies.
Study 030 was conducted in 2000 among healthy adults 
who were 18–55  years old and living in the village of 
Kombewa in the Nyanza Province of western Kenya [1]. 
Study participants who met the study entry criteria were 
first treated for 3 days (day −5 to day −3) with halofan-
trine (at 250 mg once daily). At the end of the clearance 
period (on day 0), study participants who were free from 
malaria parasitaemia, as confirmed by a sample for thick 
blood smear taken on day −2, were randomized into 
the tafenoquine 200-mg, mefloquine 250-mg or placebo 
group. The maintenance period lasted for 24 weeks with 
weekly administration of study drugs after 3 days of load-
ing doses (day 0–day 2). After the treatment period, study 
participants attended weekly follow-up safety visits until 
week 28. During the maintenance period, subjects who 
tested positive for Plasmodium species were considered 
prophylactic failures and where withdrawn from treat-
ment. They were entered into the safety follow-up phase 
of the study and given treatment such as quinine or doxy-
cycline. A schematic for this study is displayed in Fig. 1. 
Peak malaria season in western Kenya runs from May to 
July, the first dose of prophylaxis medication was given in 
May of 2000 and the final dose of prophylaxis medication 
was given in October of 2000 [7]. The protocol and state-
ment of informed consent were approved by KEMRI and 
the US Army Human Subjects Research Review Board 
(HSRRB) prior to study initiation.
Study 043 was conducted in 1997 among healthy 
adults who were 18–55  years old and living in the vil-
lage of Ndori, Nyanza Province, Kenya [2]. Study par-
ticipants who met the study entry criteria were given a 
three-day (day 0–day 2) eradication course of halofan-
trine (at 250 mg once daily). On day 7, after confirmation 
of being parasitaemia-free by blood smear samples, they 
were then randomized into one of four groups to receive 
one of three dosage regimens of tafenoquine (400-, 200- 
or 400-mg as a loading dose only) or a placebo regimen. 
For the 400- and 200-mg groups, the maintenance period 
lasted for a period of 10–15  weeks with weekly tafeno-
quine administration at the same dosage level as the 
Fig. 1 Study schematic for Study 030
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loading doses taken on days 7–9. With the exception of 
the loading doses, study participants in the tafenoquine 
400-mg loading dose only group did not receive addi-
tional tafenoquine doses during the maintenance period. 
After the maintenance period, study participants were 
followed for an additional 4  weeks (Fig.  2). Participants 
received prophylaxis between May 1997 and September 
1997. Details regarding informed consent, treatment of 
symptomatic failures and the institutional review board 
are provided in the original publication [2].
Study 045 was conducted in 1998 among healthy adults 
(aged 18–60 years for men and 40–60 years for women) 
living in the Kassena Nankana District of northern Ghana 
[3]. All study participants initially completed a course of 
eradication treatment of quinine (10 mg/kg tid) for 4 days 
followed by doxycycline (100  mg po bd) for 7  days and 
primaquine (30 mg daily) for 14 days. Five days later, after 
confirmation of being parasitaemia-free by blood smear 
samples, study participants were randomized into one 
of the four tafenoquine regimens (25-, 50-, 100- or 200-
mg), the mefloquine 250-mg group or the placebo group. 
The weekly maintenance period lasted for 12  weeks 
after 3 days of daily loading doses corresponding to the 
randomized treatment. There was a follow-up period for 
an additional 4 weeks after drug administration ended. A 
schematic for this study is displayed in Fig. 3. The major 
malaria season in northern Ghana runs from May to 
October with a peak in August, the first dose of prophy-
laxis medication was given in May of 2000 and the final 
dose of prophylaxis medication was given in October of 
2000 [8]. Details regarding informed consent, treatment 
of symptomatic failures and institutional review board 
are provided in the original publication [3].
The following were the major exclusion criteria used by 
each of the original studies:
  • Presence of clinically significant abnormalities (that 
included but were not limited to abnormal hepatic 
or renal function) as determined by history, physical 
examinations or routine blood chemistries or haema-
tology values or any medical condition that, in the 
opinion of the investigator, made the subject unsuit-
able to enter the study.
  • Use of any other anti-malarial product (excluding 
those taken during the clearance period) within the 
previous 2 weeks.
Fig. 2 Study schematic for Study 043
Fig. 3 Study schematic for Study 045
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  • Hypersensitivity to any of the study drugs, especially 
to any other 8-aminoquinolines.
  • Presence of glucose-6-phosphate dehydrogenase 
(G6PD) deficiency. In Study 030, glucose 6 phosphate 
dehydrogenase deficiency (G6PD) status was deter-
mined on two occasions during the screening period 
using standard laboratory tests (Sigma Diagnostics 
kit, Procedure #203—fluorescence of sample vs nor-
mal, intermediate and deficient controls). The same 
technique was used for both tests. Only subjects with 
a ‘normal’ reading on both occasions were eligible for 
the study [1]. In Study 043, G6PD status was deter-
mined using Sigma Diagnostics kit [2]. In Study 045, 
G6PD deficiency was determined by two separate 
qualitative tests using distinct methods—visual dye 
and filter paper [3].
  • Use of investigational drugs (new chemical entities 
not registered for use) within 30  days or five half-
lives, whichever was longer.
  • Positive serum beta-human chorionic gonadotropin 
test results (tested during screening and within 48 h 
of the first drug administration and approximately 
monthly thereafter), pregnancy or lactation or, in the 
opinion of the investigator, risk of becoming preg-
nant.
Studies had various definitions of abnormal laboratory 
values for haemoglobin, platelets, white blood cell count, 
and creatinine and alanine aminotransferase. Typically, 
abnormal laboratory values were defined as more than 
twice the upper limit of normal for that subject’s age. 
Some studies (Studies 030 and 045) excluded individuals 
with histories of psychiatric disorders or personal or fam-
ily histories of seizures. In addition, Study 030 excluded 
anyone with an abnormal electrocardiogram finding, par-
ticularly an extended QTc interval >0.42 s.
Efficacy data from the original studies
Efficacy data collection
The primary efficacy endpoint for all studies was prophy-
lactic outcome (success/failure) at the end of the prophy-
lactic treatment phase. Prophylactic outcome was based 
on the absence/presence of asexual stage parasites of any 
Plasmodium species on a blood smear. For efficacy data 
collection, duplicate thick and thin smears were prepared 
and stained with Giemsa and each slide was read by two 
separate microscopists; each microscopist was blinded to 
the other’s diagnosis. Asexual stage parasites in 50 high-
power fields were counted and reported as the number 
of parasites per 500 white blood cells; a minimum of 200 
high-powered fields were to be examined before a slide 
could be declared negative. Negative/positive discrepan-
cies between the two microscopists were resolved by a 
third microscopist, who usually was a senior microsco-
pist, by re-reading the slide. The result of this re-reading 
of the slide was considered final.
All studies, except Study 043, considered a study par-
ticipant a prophylactic failure based on the first positive 
smear result of any malaria species. In Study 043, a sec-
ond confirmatory blood sample was required to be taken 
within 7 days of when the first smear reading was posi-
tive. Prophylactic failure was only declared if the con-
firmative smear reading was also positive.
Special note on Study 030 microscopy data
During the conduct of Study 030, it was found that 
unusually high proportions of the participants failed 
prophylaxis for all three treatment groups (75/101 for 
tafenoquine, 85/98 for mefloquine, and 91/99 for pla-
cebo at the time of review). This led to the setting up of 
an Independent Data Monitoring Committee (IDMC) 
and a series of investigations to eliminate possible tech-
nical problems. The technical investigations focused on 
(1) slide reading, (2) parasite resistance, (3) drug pack-
aging, (4) analysis of pharmacokinetic samples, and (5) 
procedural errors. Drug supply packaging and stability 
were found to be in order, and analysis of blood sam-
ples showed tafenoquine at target levels. As a part of the 
investigation, the original slides were re-read by Naval 
Medical Research Unit 2 (NAMRU-2) in Jakarta, Indone-
sia, and the Australian Malaria Institute (AMI).
There were two batches of slides sent to be re-read. The 
first batch of 364 slide pairs was sent to NAMRU-2 whilst 
the study was still ongoing. These were all of the first pos-
itive slides (113 duplicate pairs) up to approximately week 
12, plus a random selection of negative slides (251 dupli-
cate pairs). A second batch, which included all remain-
ing positive slides that could be located at the study 
site plus a randomly selected number of negatives, was 
also shipped to NAMRU-2 for re-read at the end of the 
study. NAMRU-2 microscopists followed the USAMRU-
K slide reading SOP that was being used for the study. 
Each slide was independently read by two readers. Any 
discrepancies were adjudicated by a third, senior micros-
copist whose decision was considered the final result. 
The re-reading was blinded, i.e. the microscopist did not 
know whether the slide had been originally categorized 
by USAMRU-K as positive or negative. The results are 
shown in Table  1. Of the 113 slides identified as posi-
tive by the local slide readers in Kenya, only 19 were also 
read positive by NAMRU-2. The re-reading at NAMRU-2 
resulted in an overall concordance rate (i.e. slides deter-
mined either as positive at both sites or negative at both 
sites) of 74.8  % (264/353 not including unevaluable 
slides) and a positive concordance rate of only 17.6  % 
(19/108). Following the re-read by NAMRU-2, a subset 
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consisting of the 113 positive slide pairs was sent to a 
world-leading malaria parasite morphologist at AMI for 
a further re-read. Their conclusion was also that only 19 
of the 113 USAMRU-K positives contained malaria para-
sites. Of these 19, sixteen were the same slide pairs as the 
NAMRU-2 positive slides; AMI also reported a further 3 
slide pairs to be positive which NAMRU-2 had reported 
as negative and 3 slide pairs as negative which NAMRU-2 
reported as positive. No statistical comparisons between 
the NAMRU-2 and AMI readings were made because it 
cannot be guaranteed that the identity of the NAMRU-2 
positive slides was not disclosed to AMI.
In parallel, and in concert with this conclusion, the 
IDMC conducted an unblinding of parasitaemia results 
from the center and identified low apparent protective 
efficacies for both tafenoquine and mefloquine groups. 
Taking this into consideration, plus a review of serious 
adverse event data from the study, the IDMC concluded 
that the study should continue in order to meet second-
ary objectives of evaluating the long-term safety and effi-
cacy of tafenoquine.
A comparison of the original slide-reading as per-
formed at USAMRU-K with the result of the re-reading 
performed at NAMRU-2 is shown in Table  2 for all re-
read slides, including those re-read after study comple-
tion, irrespective of treatment group. The all re-read 
slide set included all slides which could be readily located 
which were diagnosed as positive by USAMRU-K plus 
a random selection of negative slides diagnosed by the 
USAMRU-K slide-readers.
Based on the cause identified for the higher than 
expected failure rate being the microscopists’ false posi-
tive readings, it is reasonable to conclude the princi-
ple analysis results from the study cannot therefore be 
treated as an accurate reflection of the true chemopro-
phylactic efficacy of tafenoquine. On the other hand, with 
the exception of the errors in slides read by USAMRU-K, 
study 030 was a well-executed study. Among the original 
study ITT set of 306 study participants, 289 of them have 
at least one valid slide re-read data by NAMRU-2 avail-
able (Table 3). A valid slide re-read is one that resulted in 
either positive or negative classification. In addition, the 
selection of the slides for re-read does not appear to bias 
the outcomes in anyway. The accuracy and reliability of 
the results of the re-read slides have been confirmed by 
the second re-read of a subset of slides by AMI. There-
fore, it has been determined that the slide re-read data 
can be used as a reasonable proxy to investigate the pro-
phylactic efficacy of tafenoquine. Details regarding the 
investigation of false-positive slide reading results and 
the validation of the slide data re-read by AMI are pro-
vided in Additional file 1.
Definitions used in unified efficacy analysis
Prophylactic phase
For the unified efficacy analysis, the prophylactic phase 
is defined from the date of the first dose of study drug 
administration until the date of the last dose plus one 
additional scheduled maintenance dosing interval. For 
all three studies, the prophylactic phase ended at 1 week 
after the date of the last maintenance dose.
Primary efficacy analysis set
This set is defined as all study participants who met the 
following five criteria:
1. Completed the clearance phase successfully,
2. Were randomized to a study treatment group,
3. Completed the loading dose phase,
4. Received at least one dose of study drug in the pro-
phylactic phase, and
5. Had at least one usable blood smear result in the pro-
phylactic phase.
This definition is slightly different from the ITT set 
defined in the Food and Drug Administration (FDA) 
draft guidance [9], which defines the ITT set as the set 
of subjects who had completed the clearance phase suc-
cessfully, had been randomized and had received at least 
one dose of study drug. Due to this difference, the pri-
mary analysis set used for the unified analyses will be 
referred to as the modified ITT (mITT) set hereafter. 
Table 1 Comparison of  USAMRU-K and  NAMRU-2 slide-
readings for Study 030
USAMRU-K US Army Medical Research Unit—Kenya, NAMRU-2 Naval Medical 
Research Unit-2
USAMRU-K Reading NAMRU-2 reading
Positive Negative Unevaluable Total
Positive 19 89 5 113
Negative 0 245 6 251
Total 19 334 11 364
Table 2 Study 030 slide re-reading results by NAMRU-2
a One participant had two negative slide results recorded on the same date
Original reading NAMRU-2 re-reading
Positive Negative Missing Total
Positive 31 220a 0 251
Negative 5 507 0 512
Missing 0 3 0 3
Total 36 730 0 766
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This definition is used to be consistent with the primary 
analysis sets used in the original studies, which were all 
designed and conducted well before the publication of 
the FDA guidance.
Although not used in the analyses presented here, the 
FDA ITT set (referred to as ITT) is displayed alongside 
the mITT set in Table 4. As can be seen, there are mini-
mal differences between the two sets. Also, it can be seen 
from Table  4 that the amount of missing data is below 
10  % for the treatment group of interest—tafenoquine 
200-mg weekly. For Study 030, the last two criteria were 
modified to include all study participants with at least 
one valid re-read smear result. A valid re-read smear 
result was a re-read record with a classification of either 
positive or negative and with a collection date that was 
on or after the date of the first dose. If a smear re-read 
result existed in both the NAMRU-2 and AMI data, the 
AMI result was used in the unified analysis.
Prophylactic failure
For the purpose of the unified analysis, a study partici-
pant was considered a prophylactic failure if during the 
prophylactic phase at least one positive smear from the 
participant was present. When raw smear data were not 
available, prophylactic outcome classification of the origi-
nal study was used for the unified analysis.
Estimation of protective efficacy
Protective efficacy (PE) was defined as the percent reduc-
tion in the incidence density (ID) of prophylactic failures 
(all species) in those study participants who received 
tafenoquine (or mefloquine) compared to placebo, which 
was calculated as follows:
where IDp is the incidence density of prophylactic failure 
in the placebo group, IDt is the incidence density of pro-
phylactic failure in the tafenoquine group (or mefloquine 
group), and IDRt,p is the incidence density ratio (IDt/IDp) 
of the treatment group [tafenoquine (or mefloquine)] rel-
ative to placebo.
(1)






= (1− IDRt,p)× 100
Table 3 Classification of subject IDs with valid re-read data
Valid re-read slides are those with either an outcome of “positive” or “negative” and were collected on or after the 1st dose
Treatment group (randomized and received at least one dose)
Placebo (N = 101) TQ 200 mg (N = 104) MQ 250 mg (N = 101) Total (N = 306)
No. of subjects with valid re-read results 93 100 96 289
No. of subjects with positive smears 31 2 2 35
No. of subjects without positive smears 62 98 94 254
No. of subjects without valid re-read results 8 4 5 17
Table 4 Study participant disposition by individual study
Percentages are based on the number of randomized study participants in each treatment group of each study
ITT intent-to-treat, mITT modified intent-to-treat
Study Treatment Randomized ITT mITT Total
030 Placebo 101 (100.0 %) 93 (92.1 %) 93 (92.1 %) 101
Tafenoquine 200-mg weekly 104 (100.0 %) 100 (96.2 %) 99 (95.2 %) 104
Mefloquine 200-mg weekly 101 (100.0 %) 96 (95.0 %) 96 (95.0 %) 101
043 Placebo 62 (100.0 %) 61 (98.4 %) 60 (96.8 %) 62
Tafenoquine 400-mg load only 64 (100.0 %) 60 (93.8 %) 57 (89.1 %) 64
Tafenoquine 200-mg weekly 61 (100.0 %) 55 (90.2 %) 55 (90.2 %) 61
Tafenoquine 400-mg weekly 62 (100.0 %) 59 (95.2 %) 57 (91.9 %) 62
045 Placebo 96 (100.0 %) 94 (97.9 %) 94 (97.9 %) 96
Tafenoquine 25-mg weekly 95 (100.0 %) 93 (97.9 %) 93 (97.9 %) 95
Tafenoquine 50-mg weekly 94 (100.0 %) 93 (98.9 %) 91 (96.8 %) 94
Tafenoquine 100-mg weekly 94 (100.0 %) 94 (100.0 %) 94 (100.0 %) 94
Tafenoquine 200-mg weekly 94 (100.0 %) 93 (98.9 %) 91 (96.8 %) 94
Mefloquine 250-mg weekly 48 (100.0 %) 46 (95.8 %) 46 (95.8 %) 48
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The ID was defined as the cumulative number of pro-
phylactic failures divided by the sum of time at risk for 
each subject within each treatment group. For subjects 
who did not discontinue from the study early and did 
not have positive smear results, their time at risk was the 
same as the length of the prophylactic phase. For sub-
jects who had positive smears, their time at risk stopped 
on the date of the first positive smear. For subjects who 
discontinued early, their time at risk stopped at the time 
they discontinued. When a discontinuation date was 
not available, either the last contact date or the last dose 
date was used, depending on which one was available. 
Total person-time at risk for the treatment groups was 
obtained as the sum of the time at risk for each subject in 
the group.
The incidence density ratio (IDR) in Eq.  (1) was esti-
mated using a Poisson regression model with no inter-
cept and treatment as covariate. The logarithm of total 
time at risk for each treatment group was used as an off-
set. PE was calculated from PE = (1 – IDR). An approach 
based on the likelihood ratio test was used for construct-
ing the corresponding 95  % 5 CI. The calculation was 
implemented using SAS software version 9.2.
Data integration
Rationale for the pooling of subject-level records 
across studies
The rationale for the unified analysis and pooling of sub-
ject-level records of similar regimens of the three studies 
are due to (1) the identically defined study objectives and 
primary efficacy endpoints, and almost identical study 
designs, (2) similar study populations (Africans resident 
in an areas of high malaria transmission), (3) similar sam-
ple sizes of the respective regimens, and (4) the availabil-
ity of subject-level study records. This analysis strategy 
fully utilizes the data available and is strongly supported 
by the sensitivity analysis presented below. Two pooled 
data sets were created by merging subject-level records 
of the respective regimens: (1) placebo and tafenoquine 
(200-mg) groups from Studies 030, 043 and 045; and (2) 
placebo, mefloquine and tafenoquine (200-mg) groups 
from Studies 030 and 043. Mefloquine was the histori-
cal standard of care. The 200-mg dose of tafenoquine is 
the intended dose for marketing and achieves the desired 
steady-state trough concentrations [6].
As a sensitivity analysis of the method of pooling of 
the subject-level results across studies, we combined 
the study-specific protective efficacy estimates from 
the individual tafenoquine 200-mg weekly regimens 
(intended dose) using meta-analysis methodologies. To 
help determine whether a fixed effect or random effects 
model should be used to combine the individual PE esti-
mates, the heterogeneity (variability) of the individual PE 
estimates was assessed using Cochran’s Q statistic [10], 
and the I2 and H statistics of Higgins and Thomson [11]. 
The latter is sometimes recommended when the meta-
analysis is based on a small number of studies [12].
The approach in DerSimonian and Laird [13] was used 
to estimate the between study variance in PE estimates 
and, subsequently, I2 and H. If the Q-statistic was less 
than the number of studies (2 or 3), the I2 and H statis-
tics were truncated to their minimum values, respectively 
[11]. Based on the results of those investigations (see 
“Results” section below for more details), a fixed effect 
model [14] was used for the meta-analysis. It is worth 
noting that this method is equivalent to the better known 
Mantel–Haenszel method [14].
Disposition and early withdrawal
Table  4 shows the disposition of subjects by individual 
original study. The main reason for the reduction in the 
number of subjects from the randomized to the mITT 
population was due to screening failure. The second most 
common reason was the lack of blood smears for the 
efficacy assessment. Table 5 shows reasons and number 
of early withdrawals from the original studies. The large 
number of early withdrawals due to insufficient thera-
peutic effect observed in the tafenoquine and mefloquine 
groups in Study 030 reflected the false-positive smear 
readings by the original study site. In the original Study 
030, all subjects who were considered to have had posi-
tive smears were removed from the study prior to the end 
of the treatment period.
Key demographics
Table  6 shows only the key demographics of subjects 
from the pooled data of the three studies. Among the dis-
played demographic characteristics, there is no obvious 
imbalance between the placebo and tafenoquine treat-
ment groups.
Results
Efficacy results, from individual studies or pooled data-
sets, were obtained using a unified set of working defi-
nitions, as presented in the Methods section. Individual 
study efficacy results are summarized in Table  7 and 
pooled analyses are summarized in Table 8. The number 
of prophylactic failures includes all species of malaria.
Individual study results (Table 7) of Study 043 using the 
unified definitions (instead of original study definitions) 
are different from the previously published results in 
some notable ways. The number of prophylactic failures 
in Study 043 matched that obtained from the original 
efficacy results. However, six more subjects (one in the 
placebo arm, three in the tafenoquine 400-mg arm and 
two in the tafenoquine 200-mg arm) were included in the 
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mITT set of the unified analysis. Those subjects each had 
one valid smear data record but with missing blood sam-
ple collection dates. For the unified analysis, they were 
assumed to have been collected during the prophylactic 
phase of the study and were included in the analysis.
Protective efficacy for the pooled analyses (Table 8) was 
based on the respective pooled treatment groups from 
each of the individual studies in the pool.
The pooling increases the sample sizes for analysis, 
and, as a consequence, the pooled results provided more 
precise estimates of the corresponding PEs (i.e., nar-
rower CI). The PEs for the pooled analyses (Table  8) of 
tafenoquine load plus weekly maintenance at 200-mg 
were consistent with that of each of the individual studies 
(Table 7), although with a substantially higher lower limit 
for the 95 % CI of the PE. The pooled PE of tafenoquine 
load plus weekly maintenance at 200-mg relative to pla-
cebo for Studies 030, 043, and 045 was 93.1 % (95 % CI 
89.1–95.6 %, total N = 492).
From individual study results of Studies 030 and 045, 
PE values did not differ appreciably between load plus 
weekly maintenance dose at tafenoquine 200-mg and 
mefloquine 250-mg. The PEs of the pooled data for 
tafenoquine load plus weekly maintenance at 200-mg 
weekly and mefloquine load plus weekly maintenance 
at 250-mg weekly relative to placebo for Studies 030 
and 045 were 93.5 % (95 % CI 88.6–96.2 %) and 94.5 % 
(95  % CI 88.7–97.3  %), respectively (total N  =  519). 
The lower confidence limits for PEs of both pooled 
results are practically indistinguishable at approxi-
mately 89 %.
Load plus weekly maintenance of tafenoquine at doses 
of 50- and 100-mg from Study 045, but not 25-mg, exhib-
ited similar point estimates of PE. The PE of tafenoquine 
regimens of 3  days of loading dose at 400-mg with and 
without follow-up 400-mg weekly maintenance doses 
were 93.7 % (95 % CI 85.4–97.3 %) and 81.0 % (95 % CI 
66.8–89.1 %), respectively.
Figure 4 shows the estimated PEs and their 95 % CIs for 
both the individual and pooled studies.
Table 9 provides measures of heterogeneity in PE esti-
mates from the individual studies used in the pooled 
analysis (Table 8). Results in Table 9 provide strong evi-
dence for consistency (little heterogeneity) amongst the 
PEs from the individual studies. As a result, a fixed effect 
meta-analysis model was used to provide an overall sum-
mary estimate of PE. Results of the meta-analysis for the 
200-mg weekly regimen are given in Table 10. The simi-
larities in the PE estimates (and CIs) in Table  8 (simple 
pooling) and Table 10 (meta-analysis using a fixed effect 
model) are evident. It should be noted that other meta-
analysis methods (fixed or random effects) including the 
familiar Mantel-Haenzel method for a stratified analysis, 
yield similar results.
Table 5 Primary reason for early discontinuation among all randomized study participants by study
The percentage for each reason is based on the total number of subjects withdrawing early in each treatment group
TQ tafenoquine, MQ mefloquine, NR information not reported in the original studies
a Insufficient therapeutic effect or confirmed parasitemia
b Moved outside of endemic area with no reported malaria infection










Movedb Other or 
unknown
030 Placebo 100 0 93 (93.0 %) 2 (2.0 %) 3 (3.0 %) NR 2 (2.0 %)
TQ 200-mg weekly 97 2 (2.1 %) 88 (90.7 %) 1 (1.0 %) 3 (3.1 %) NR 3 (3.1 %)
MQ 250-mg weekly 97 1 (1.0 %) 89 (91.8 %) 3 (3.1 %) 1 (1.0 %) NR 3 (3.1 %)
Total 294 3 (1.0 %) 270 (91.8 %) 6 (2.0 %) 7 (2.4 %) NR 8 (2.7 %)
043 Placebo 27 0 22 (81.5 %) 1 (3.7 %) 4 (14.8 %) NR 0
TQ 400-mg load only 18 1 (5.6 %) 5 (27.8 %) 2 (11.1 %) 9 (50.0 %) NR 1 (5.6 %)
TQ 200-mg weekly 13 1 (7.7 %) 1 (7.7 %) 8 (61.5 %) 3 (23.1 %) NR 0
TQ 400-mg weekly 10 0 0 6 (60.0 %) 4 (40.0 %) NR 0
Total 68 2 (2.9 %) 28 (41.2 %) 17 (25.0 %) 20 (29.4 %) NR 1 (1.5 %)
045 Placebo 72 NR 62 (86.1 %) NR NR NR 10 (13.9 %)
TQ 25-mg weekly 35 NR 26 (74.3 %) NR NR NR 9 (25.7 %)
TQ 50-mg weekly 16 NR 2 (12.5 %) NR NR NR 14 (87.5 %)
TQ 100-mg weekly 8 NR 0 NR NR NR 8 (100.0 %)
TQ 200-mg weekly 18 NR 1 (5.6 %) NR NR NR 17 (94.4 %)
MQ 250-mg weekly 4 NR 0 NR NR NR 4 (100.0 %)
Total 153 NR 91 (59.5 %) NR NR NR 62 (40.5 %)
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Discussion
Currently available medications for malaria prophylaxis 
include mefloquine, doxycycline, atovaquone-proguanil 
and chloroquine. Because of the importance of compli-
ance in an occupational health setting, mefloquine has 
historically been the preferred choice as it can be admin-
istered weekly and is effective in areas of chloroquine-
resistant malaria [15, 16]. However, the association of 
mefloquine with adverse neuropsychiatric effects has 
curtailed its use (e.g., by the US military  [17]). Tafeno-
quine is a logical alternative to mefloquine for G6PD-
normal individuals as it can also be administered weekly 
and has activity against P. vivax hypnozoites.
As discussed elsewhere, traditional placebo-controlled 
or active-controlled (non-inferiority) trials to determine 
the efficacy of prophylactic drugs in the intended popula-
tion, non-immune travelers, are usually not feasible [18]. 
A placebo-controlled trial in this population is unethi-
cal because these individuals cannot be hospitalized in 
a deployed setting and P.  falciparum is potentially fatal 
[18]. Given the expected very low failure rates, a non-
inferiority design will necessitate very large sample sizes 
for an efficacious drug [19]. The demonstration that 
tafenoquine at the intended dose was effective in non-
immune subjects [5, 6] was due to a unique combination 
of circumstances that is unlikely to be repeated: fortunate 
timing with a large non-immune deployment to a malari-
ous area, a study drug ready to be tested, a competent 
study team and a low incidence of post-exposure P. vivax 
relapses that allowed an attack rate to be determined 
retrospectively.
As a consequence of these challenges, the market-
ing applications for all other prophylactic anti-malarial 
agents submitted to regulators have incorporated pla-
cebo-controlled studies that enrolled residents of regions 
of high malaria transmission in malaria-endemic coun-
tries. In most cases, as adults, such study subjects, due 
to prior exposure to malaria, generally do not contract 
Table 7 Protective efficacy based on mITT by individual study
CI confidence interval, mITT modified intent-to-treat, N number of subjects, PE protective efficacy
a Median time for treatment groups with small number of events cannot be estimated due to the sparseness of the data
b Incidence density rate is expressed in terms of number of prophylactic failures per 100 person-years










30 Placebo 93 30 10.1 13.26 226.2
Tafenoquine 200-mg weekly 99 2 NA 20.96 9.5 95.8 82.3 99
Mefloquine 250-mg weekly 96 2 NA 17.9 11.2 95.1 79.3 98.8
43 Placebo 60 54 7.0 7.68 703.2
Tafenoquine 400-mg load only 57 16 NA 11.96 133.7 81 66.8 89.1
Tafenoquine 200-mg weekly 55 7 NA 12.21 57.3 91.8 82.1 96.3
Tafenoquine 400-mg weekly 57 6 NA 13.58 44.2 93.7 85.4 97.3
45 Placebo 94 86 4.6 9.65 891.6
Tafenoquine 25-mg weekly 93 58 7.7 15.32 378.7 57.5 40.7 69.6
Tafenoquine 50-mg weekly 91 13 NA 20.67 62.9 92.9 87.4 96.1
Tafenoquine 100-mg weekly 94 11 NA 21.99 50 94.4 89.5 97
Tafenoquine 200-mg weekly 91 12 NA 21.27 56.4 93.7 88.4 96.5
Mefloquine 250-mg weekly 46 6 NA 10.77 55.7 93.8 85.7 97.3
Table 8 Protective efficacy based on mITT by pooled group
CI confidence interval, mITT modified intent-to-treat, N number of subjects, PE protective efficacy
a Incidence density rate is expressed in terms of number of prophylactic failures per 100 person-years








030 and 045 Placebo 187 116 22.91 506.3
Tafenoquine 200-mg weekly 190 14 42.23 33.2 93.5 88.6 96.2
Mefloquine 250-mg weekly 142 8 28.67 27.9 94.5 88.7 97.3
030, 043 and 045 Placebo 247 170 30.59 555.7
Tafenoquine 200-mg weekly 245 21 54.44 38.6 93.1 89.1 95.6
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symptomatic malaria even when parasitaemic. Also, 
malaria prophylactic drugs are generally not used and/
or are not recommended in such regions. Historically, 
therefore, the administration of placebo has been con-
sidered ethical, and approvals for such studies have been 
granted by reputable local and international institutional 
review boards. In such studies, an attack rate can be cal-
culated from the placebo arm. As a consequence, the 
efficacy of both atovaquone-proguanil and tafenoquine, 
which were both developed in parallel in the 1990s, were 
evaluated primarily in these populations.
At the intended dose in the intended malaria naive pop-
ulation, tafenoquine exhibited a point estimate of pro-
phylactic efficacy of 100 % (95 % CI 93–100 %, n = 490) 
compared with 100 % (95 % CI 79–100 %, n = 161) for 
mefloquine [5, 6]. The efficacy of tafenoquine and the 
Fig. 4 Plot of estimated protective efficacies and 95 % confidence intervals
Table 9 Homogeneity of estimates of protective efficacy of pooled studies
* p value is from a Chi square test of homogeneity of PE s between studies with degree of freedom k − 1, where k is the number of studies
a Between-study variance is estimated using the random effect model of DerSimonian and Laird [13]
b H and I2 calculations are based on Higgins and Thomson [8] and 95 % confidence intervals are based on Biggerstaff and Tweedie
Studies pooled Treatment Cochran’s Q-test Between study  
variancea
Higgins and Thompson statisticsb
Q Stat P value* H (95 % CI) I2 (95 % CI)
030 and 045 Placebo
Tafenoquine 200 mg weekly 0.26 0.61 0.00 1.00 (1.0, 1.7) 0.00 (0.0, 0.7)
030, 043 and 045 Placebo
Tafenoquine 200 mg weekly 0.70 0.71 0.00 1.00 (1.0, 1.4) 0.00 (0.0, 0.5)
Page 12 of 13Dow et al. Malar J  (2015) 14:473 
similarity of its prophylactic effect to that of mefloquine 
were also evident from the studies conducted in high 
transmission areas in malaria-endemic countries that 
were analysed here. In the three separate placebo-con-
trolled studies (Studies 045, 043 and 030), the intended 
dose was found to be more effective than placebo, and the 
magnitude of the prophylactic effect was similar between 
all three studies, whether analysed individually or pooled 
(Tables 7, 8). In addition, the magnitude of the prophylac-
tic effect was similar to that of mefloquine in both studies 
(Studies 043 and 030) in which it was included (Tables 7, 
8) and to that of mefloquine reported elsewhere (94 %).
Amongst residents of Africa, the estimates of efficacy 
were slightly lower for mefloquine and tafenoquine (94.5 
and 93.5  %, respectively, Table  8) than in non-immune 
subjects. In a recent paper we speculated that the dif-
ference between the apparent efficacy is of a magnitude 
that could be explained by a small false positive error 
rate in microscopy reads in the high attack rate setting 
of the African studies [6]. The data also imply that doses 
lower than that intended might be efficacious because 
a loading-only regimen was partially efficacious and 
because weekly regimens of lower doses (50- and 100-
mg) appeared to be as efficacious as the weekly 200-mg 
regimen and mefloquine. However, based on tafenoquine 
concentrations associated with symptomatic break-
throughs in Thai soldiers and non-immune North Ameri-
can volunteers, the proposed threshold concentration 
for protection in the intended population is 80  ng/ml 
[20]. Furthermore, trough concentrations above this level 
can be maintained at the intended dose, but not indefi-
nitely with monthly administration of 400  mg following 
a 1200  mg loading dose. A lower dose in malaria-naïve 
subjects could be considered once more information 
about tafenoquine concentrations in association with 
symptomatic failures is known.
Thus far, regulatory dossiers for all prophylactic anti-
malarial agents incorporate data from efficacy studies 
conducted in subjects resident in the high transmission 
zones of malaria endemic countries. Since the last time 
a prophylactic anti-malarial agent, atovaquone-progua-
nil, was approved in 2001, evolving international ethics 
standards have led many to argue that such studies may 
not be ethical [18]. This is primarily due to the percep-
tion that the residents of high malaria transmission zones 
do not benefit from malaria prophylaxis, as symptomatic 
malaria is infrequent in this population even when para-
sitaemia is microscopically confirmed. However, this per-
ception may not be true to the same extent in the future 
as it arguably once was. As the incidence of malaria 
declines in endemic countries but is not eradicated, the 
proportion of malaria naïve and non-immune adults will 
increase. These individuals could in theory benefit from 
tafenoquine if they are traveling to an area of high trans-
mission within their own (or other) countries. Also, since 
tafenoquine is the only long half-life anti-malarial with 
activity against all stages of the parasite, sub-chronic reg-
imens of the drug may have a useful role for community 
prophylaxis drug in the context of accelerating malaria 
control efforts.
The most common adverse events associated with 
tafenoquine are known and include gastrointestinal 
stress, reversible asymptomatic methaemoglobinemia, 
reversible vortex keratopathy and, in individuals with 
G6PD deficiency, haemolytic anaemia [21, 22]. Safety 
data were collected for Study 043 and 045 and were 
reported individually in the original publications [2, 3]. 
Safety data were also collected for Study 030, and were 
included in the final clinical study report included here 
as supplemental information [1]. In a future publication, 
we will report on the integrated safety and tolerability of 
tafenoquine across multiple prophylaxis studies. We hope 
that that report, together with this summary of efficacy, 
will be sufficient to allow the regulatory, health care and 
scientific communities to determine whether the poten-
tial benefits of tafenoquine are worth the risk relative to 
alternative anti-malarials that might be used for malaria 
prevention in travelers or for community prophylaxis in 
malaria endemic countries (with the applicability of alter-
natives being based on jurisdiction and intended use).
Conclusions
At the intended dose, (200  mg once per day for 3  days 
followed by weekly 200  mg maintenance doses), the 
Table 10 Protective efficacy based on mITT using a fixed effect model (meta analysis)
CI confidence interval, mITT modified intent-to-treat
a Combined estimate of PE (and CI) are based on the fixed effect model of DerSimonian and Laird [13]




030 and 045 Placebo
Tafenoquine 200-mg weekly 94.1 89.7 96.6
030, 043 and 045 Placebo
Tafenoquine 200-mg weekly 93.4 89.6 95.8
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pooled protective efficacy of tafenoquine in three pla-
cebo controlled studies was 93.1 % (95 % CI 89.1–95.6 %; 
total N = 492). In the two studies where mefloquine was 
included as a comparator arm, the efficacy of both drugs 
was similar. Furthermore, the efficacy of tafenoquine was 
dose-related and similar across three placebo-controlled 
studies. Collectively these studies support prior observa-
tions that tafenoquine and mefloquine have similar effi-
cacy in malaria naïve individuals.
Abbreviations
AMI: Australian Malaria Institute; CI: confidence interval; FDA: food and drug 
administration; G6PD: glucose-6-phosphate dehydrogenase; ID: identification; 
ITT: intent-to-treat; mITT: modified intent-to-treat; NAMRU-2: Naval Medical 
Research Unit 2; PE: protective efficacy.
Authors’ contributions
GSD led the technical team that performed the analysis and wrote the manu-
script. WM, JL and DT developed the analysis framework for the study and 
assisted with manuscript preparation. GL, BH, ST, AL, and BG performed the 
analysis, contributed to the writing of the manuscript and preparation of the 
tables and figures. BS led the tafenoquine development team for USAMMDA 
and assisted with data analysis and manuscript review. All authors read and 
approved the final manuscript.
Author details
1 60° Pharmaceuticals LLC, Washington, DC 20036, USA. 2 PPD, Inc., Richmond, 
VA 23230, USA. 3 USAMMDA, Ft Detrick, MD 21702, USA. 
Acknowledgements
The authors acknowledge the contributions of Brandon Graham, An Li, Blaine 
Byars, Varsha Vadrevu, Gayan Makumburage, Kelly Detz, Mrugesh Patel, Lisa 
Kerr, Venkateshwaran Lajapathirajan and Yi-Ting Tsai for providing statistical 
analysis and programming support. The authors acknowledge the contribu-
tion of the study team and volunteers who participated in Studies 043, 030 
and 045, without whom it would not have been possible to prepare this 
manuscript.
Competing interests
Geoffrey Dow, Bryan Smith and William McCarthy have personal and profes-
sional scientific interest in securing the regulatory approval of tafenoquine. 
Bryan Smith is the product manager for tafenoquine at USAMMDA. Geoffrey 
Dow was a senior technical advisor to the tafenoquine product develop-
ment team at the time of preparation of this manuscript, and is now the CEO 
of 60 Degrees Pharmaceuticals, the US Army’s licensee for tafenoquine for 
prophylaxis. William McCarthy was the senior in house statistician during the 
preparation of this manuscript. The other authors declare that they have no 
competing interests.
Received: 23 June 2015   Accepted: 5 November 2015
References
 1. US Army Unpublished Clinical Study Report. A randomized, double 
blind, placebo controlled evaluation of weekly tafenoquine (WR 
238605/SB252263) compared to mefloquine for chemosuppression 
Additional file
Additional file 1. Tafenoquine—SB 252263 (WR 238605). A randomized, 
double blind, placebo controlled evaluation of weekly tafenoquine (WR 
238605/SB252263) compared to mefloquine for chemosuppression of 
Plasmodium falciparum in Western Kenya.
of Plasmodium falciparum in Western Kenya (SB Document Number: 
SB-252263/RSD-101KZH/1), 2003.
 2. Hale BR, Owusu-Agyei S, Fryauff DJ, Koram KA, Adjuik M, Oduro AR, et al. 
A randomized, double-blind, placebo-controlled, dose-ranging trial of 
tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin 
Infect Dis. 2003;36:541–9.
 3. Shanks GD, Oloo AJ, Aleman GM, Ohrt C, Klotz FW, Braitman D, et al. A 
new primaquine analogue, tafenoquine (WR 238605), for prophylaxis 
against Plasmodium falciparum malaria. Clin Infect Dis. 2001;33:1968–74.
 4. Walsh DS, Eamsila C, Sasiprapha T, Sangkharomya S, Khaewsathien P, 
Supakalin P, et al. Efficacy of monthly tafenoquine for prophylaxis of 
Plamodium vivax and multidrug-resistant P. falciparum malaria. J Infect 
Dis. 2004;190:1456–63.
 5. Nasveld PE, Edstein MD, Reid M, Brennan L, Harris IE, Kitchener SJ, et al. 
Randomized, double-blind study of the safety, tolerability, and efficacy 
of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune 
subjects. Antimicrob Agents Chemother. 2010;54:792–8.
 6. Dow GS, McCarthy WF, Reid M, Smith B, Tang D, Shanks GD. A retrospec-
tive analysis of the protective efficacy of tafenoquine and mefloquine 
as prophylactic antimalarials in non-immune individuals. Malar J. 
2014;13:49.
 7. Zhou G, Afrane YA, Dixit A, Atieli HE, Lee MC, Wanjala CL, et al. Modest 
additive effects of integrated vector control measures on malaria preva-
lence and transmission in western Kenya. Malar J. 2013;12:256.
 8. Aborah S, Akweongo P, Adjuik M, Atinga RA, Welanga P, Adongo P. The 
use of non-prescribed anti-malarial drugs for the treatment of malaria in 
the Bolgatanga municipality, northern Ghana. Malar J. 2013;12:266.
 9. FDA. Guidance for industry malaria: developing drug and nonvaccine 
biological products for treatment and prophylaxis. 2007.
 10. Cochran WG. The combination of estimates from different experiments. 
Biometrics. 1954;10:101–29.
 11. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. 
Stat Med. 2002;21:1539–58.
 12. Hardy RJ, Thompson SG. Detecting and describing heterogeneity in 
meta-analysis. Stat Med. 1998;17:841–56.
 13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 
1986;7:177–88.
 14. Mantel N, Haenszel MW. Statistical aspects of the analysis of data from 
retrospective studies of disease. J Natl Cancer Institute. 1959;22:719–48.
 15. Steffen R, Fuchs E, Schildknecht J, Naef U, Funk M, Schlagenhauf P, et al. 
Mefloquine compared with other malaria chemoprophylactic regimens 
in tourists visiting east Africa. Lancet. 1993;341:1299–303.
 16. Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell 
CC. Long-term malaria prophylaxis with weekly mefloquine. Lancet. 
1993;341:848–51.
 17. Department of Defense. Guidance on medications for prophylaxis of 
malaria. 2013.
 18. Dow GS, Magill AJ, Ohrt C. Clinical development of new prophylactic 
antimalarial drugs after the 5th Amendment to the Declaration of Hel-
sinki. Ther Clin Risk Manag. 2008;4:803–19.
 19. Hogh B, Clarke PD, Camus D, Nothdurft HD, Overbosch D, Gunther M, 
et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria 
prophylaxis in non-immune travelers: a randomised, double-blind study. 
Malarone International Study Team. Lancet. 2000;356:1888–94.
 20. Edstein MD, Kocisko DA, Walsh DS, Eamsila C, Charles BG, Rieckmann KH. 
Plasma concentrations of tafenoquine, a new long-acting antimalarial 
agent, in Thai soldiers receiving monthly prophylaxis. Clin Infect Dis. 
2003;37:1654–8.
 21. Leary KJ, Riel MA, Roy MJ, Cantilena LR, Bi D, Brater DC, et al. A 
randomized, double-blind, safety and tolerability study to assess the 
ophthalmic and renal effects of tafenoquine 200-mg weekly versus 
placebo for 6 months in healthy volunteers. Am J Trop Med Hyg. 
2009;81:356–62.
 22. Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko DA, Edstein MD. The 
efficacy and tolerability of three different regimens of tafenoquine 
versus primaquine for post-exposure prophylaxis of Plasmodium 
vivax malaria in the Southwest Pacific. Trans R Soc Trop Med Hyg. 
2008;102:1095–101.
